AH Bio Fund is a series of two Limited Partnership, Venture Capital, Pooled Investment Funds managed by Andreessen Horowitz.
AH Bio Fund I, L.P. specializes in Series A, seed, early-stage startup investments. The fund seeks to invest in software related biology, biotech, and medicine companies at the intersection of computer science and life sciences, with a focus on digital therapeutics, cloud technology in biology, and computational medicine robot. AH Bio Fund I raised $200M across 67 investors. It was announced on November 18, 2015.
AH Bio Fund II, L.P was announced on Dec 14, 2017 . The Andreessen Horowitz' second bio fund is a $450 million investment fund focused on the intersection of biology and engineering. As with the first bio fund, they invest across seed to growth.
In 2015, the venture firm Andreessen Horowitz launched a $200 million fund located in Menlo Park, CA, to invest in software, biology, and medicine, led by its ninth general partner, Vijay Pande. The Official name of the fund is AH Bio Fund I LP . The fund gathered $200M (18 Nov 2015) from 67 investors .
AH Bio Fund II, L.P is a venture capital fund located in Menlo Park, CA that invests in early-stage healthcare-focused information technology companies. This Andreessen Horowitz sponsored fund is led by Vijay Pande, the chair of Stanford University's chemistry department. The fund is an extension of the firm's early-stage information technology investment program, but differs in its focus on the healthcare sector.
The focus is in computational biomedicine, applying AI and ML to diagnostics and therapeutics; new bio utilities or tools that make it easier to "read", "write" or edit and synthesize DNA, as well as making advances in bioengineering itself.
AH Bio Fund I LP
This fund focuses on software companies built to enable and address biotech ideas. It makes roughly one Series A investment and 2-3 seed investments each quarter, on pace with other general partners at Andreessen Horowitz. The fund works closely with Y Combinator.
AH Bio Fund II
AH Bio Fund II invests in software companies which can benefit from the reduction in the costs of data storage, computational power, sensors to measure biological data, and genetic sequencing. AH Bio Fund II has identified computational biomedicine, new scientific utilities, and network effects in healthcare as areas of specific investment interest.
AH Bio Fund II
AH Bio Fund I LP
Chief Operating Officer
Andreessen Horowitz has a new, $450 million bio fund
Bio Fund II
Going Deeper Into Freenome
Menlo Ventures dives into data-driven healthcare investing with its newest partner
The One Health Company
Top Silicon Valley VC Andreessen Horowitz is investing $450 million into biotech
Documentaries, videos and podcasts
- Computer scienceComputer science is the study of the theoretical foundations of information and computation as well as the practical concerns for designing and building computers.
- Andreessen Horowitz (a16z)Andreessen Horowitz (also named a16z) is a US venture capital firm, founded by Marc Andresseen and Ben Horowitz in 2009.
- DNAMolecule that encodes the genetic instructions used in the development and functioning of all known living organisms and many viruses